Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Author:

Usmani Saad Z.1,Weiss Brendan M.2,Plesner Torben3,Bahlis Nizar J.4,Belch Andrew5,Lonial Sagar6,Lokhorst Henk M.7,Voorhees Peter M.8,Richardson Paul G.9,Chari Ajai10,Sasser A. Kate11,Axel Amy11,Feng Huaibao12,Uhlar Clarissa M.11,Wang Jianping11,Khan Imran12,Ahmadi Tahamtan11,Nahi Hareth13

Affiliation:

1. Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC;

2. Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;

3. Vejle Hospital and University of Southern Denmark, Vejle, Denmark;

4. Tom Baker Cancer Center–University of Calgary, Calgary, AB, Canada;

5. Cross Cancer Institute, Edmonton, AB, Canada;

6. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;

7. Department of Hematology, VU Medical Center, Amsterdam, The Netherlands;

8. Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC;

9. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

10. Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY;

11. Janssen Research & Development, LLC, Spring House, PA;

12. Janssen Research & Development, LLC, Raritan, NJ; and

13. Karolinska Institute, Division of Hematology, Department of Medicine, Karolinska University Hospital at Huddinge, Stockholm, Sweden

Abstract

Key Points A pooled analysis of 2 daratumumab trials showed no new safety signals, an overall response rate of 31%, and deep and durable responses. Median overall survival was 20.1 months; benefit was also shown in patients who achieved minimal response/stable disease.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3